allergytalk

By allergytalk

AllergyTalk is a round-up of the latest in the field of allergy and immunology by the American College of Allergy, Asthma and Immunology. In each bi-monthly episode, hosts Gerald Lee, MD, and Merin Ka... more

5

4646 ratings

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about allergytalk:

How many episodes does allergytalk have?

The podcast currently has 74 episodes available.

allergytalk episodes:

December 13, 2024Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 3 – Long-Term Management and Prophylaxis for HAE
Host: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI

Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed.

Learning Objective:
After listening to this podcast episode, participants should be better able to:
Employ strategies for long-term prophylaxis.
References:
Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022

Speaker Disclosures:
Kristin C. Sokol, MD, MS, MPH, FACAAI
Advisor: Sanofi, Genentech, SELF/Conde Nast

Aleena Banerji, MD
Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda
Researcher: Astria, Ionis, Intellia

Jonathan A. Bernstein, MD, FACAAI
Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda
Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda
Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva

This podcast miniseries is supported by a grant from Takeda.
...more
13min
December 13, 2024Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 2 – Overcoming Barriers in HAE Treatment
Episode 2: Overcoming Barriers in HAE Treatment

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO, FACAAI

This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration.

Learning Objective:
After listening to this podcast episode, participants should be better able to:
Create effective treatment plans for their specific population (minority, rural, urban)

References:
Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022

Speaker Disclosures:
Kristin C. Sokol, MD, MS, MPH, FACAAI
Advisor: Sanofi, Genentech, SELF/Conde Nast

Jonathan A. Bernstein, MD, FACAAI
Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda
Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda
Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva

Timothy J. Craig, DO, FACAAI
Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda
Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda
Independent Contractor: Kalvista, Phavaris
Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda
Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda

This podcast miniseries is supported by a grant from Takeda.
...more
21min
December 13, 2024Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies Miniseries Episode 1 – Diagnosing HAE Accurately
Host: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Aleena Banerji, MD; Timothy J. Craig, DO, FACAAI
This discussion covers the key factors in accurately diagnosing HAE, including clinical history, lab testing, and the role of genetic testing in distinguishing between HAE types. Special considerations for diagnosing pediatric patients will also be discussed.
Learning Objective:
After listening to this podcast episode, participants should be better able to:
Diagnose pediatric HAE accurately
References:
Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022
Speaker Disclosures:
Kristin C. Sokol, MD, MS, MPH, FACAAI
Advisor: Sanofi, Genentech, SELF/Conde Nast

Aleena Banerji, MD
Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda
Researcher: Astria, Ionis, Intellia

Timothy J. Craig, DO, FACAAI
Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda
Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda
Independent Contractor: Kalvista, Phavaris
Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda
Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda

This podcast miniseries is supported by a grant from Takeda.
...more
17min
December 13, 2024 Episode 47: Does Food Allergy Increase Cardiovascular Risk?
Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!
For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
CRISPR Gene-Editing Therapy for Hereditary Angioedema
Reviewed by Samantha knox
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.
Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Boiselle C, Vogel JD, Abdelhady AM, Maitland ML, McKee MD, Seitzer J, Han BW, Soukamneuth S, Leonard J, Sepp-Lorenzino L, Clark ED, Lebwohl D, Cohn DM. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med. 2024 Feb 1;390(5):432-441. doi: 10.1056/NEJMoa2309149. PMID: 38294975.
New Peanut Allergy Rare After Peanut Introduction in Infants
Reviewed by Sarah Spriet
Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants
Banerjee A, Wood R, Dunlop J, Dantzer J, Plesa M, Togias A, Keet C. Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants. J Allergy Clin Immunol Pract. 2024 Mar;12(3):645-651.e1. doi: 10.1016/j.jaip.2023.11.035. Epub 2023 Nov 29. PMID: 38036248.

IgE to Food Allergens and Cardiovascular Mortality
Reviewed by Gerry Lee
IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis
Keet C, McGowan EC, Jacobs D, Post WS, Richards NE, Workman LJ, Platts-Mills TAE, Manichaikul A, Wilson JM. IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis. J Allergy Clin Immunol. 2024 Feb;153(2):471-478.e3. doi: 10.1016/j.jaci.2023.09.038. Epub 2023 Nov 9. PMID: 37943208; PMCID: PMC10922097.

Please rate our podcast on Apple podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis
Dr. Fineman has nothing to disclose
Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended KA)
...more
25min
December 13, 2024 Episode 46: Can We Achieve Clinical Remission In Asthma?
Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!
For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Reviewed by Iris Otani
Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial.
Zhang J, Yang X, Chen G, Hu J, He Y, Ma J, Ma Z, Chen H, Huang Y, Wu Q, Liu Y, Yu L, Zhang H, Lai H, Zhang J, Zhai J, Huang M, Zou Z, Tao A. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Ann Allergy Asthma Immunol. 2024 Mar;132(3):346-354.e1. doi: 10.1016/j.anai.2023.10.029. Epub 2023 Oct 31. PMID: 37913839.
Clinical Remission in a Real-World Severe Asthma Registry
Reviewed by Tim Chow
Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.
McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. PMID: 37857423; PMCID: PMC10719453.
More Evidence Against Using Corticosteroids for Anaphylaxis
Reviewed by Iris Otani
Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data.
Delli Colli L, Al Ali A, Gabrielli S, Delli Colli M, Mule P, Lawson B, Clarke AE, Morris J, Gravel J, Lim R, Chan ES, Goldman RD, O'Keefe A, Gerdts J, Chu DK, Upton J, Hochstadter E, Bretholz A, McCusker C, Zhang X, Benor S, Simons E, Abrams EM, Protudjer JLP, Ben-Shoshan M. Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data. Ann Allergy Asthma Immunol. 2023 Dec;131(6):752-758.e1. doi: 10.1016/j.anai.2023.08.606. Epub 2023 Sep 7. PMID: 37689113.
Please rate our podcast on Apple podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis
Dr. Fineman has nothing to disclose
Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended)
...more
25min
October 17, 2024The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 3
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma

Host: Gerald B. Lee, MD, FACAAI
Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI

Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application.

Learning Objectives:
Expose the prevalence of asthma and exacerbations in the US
Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
Analyze the latest expert opinion on treatment of asthma to mitigate morbidity

Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.

Speaker Disclosures:
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose

Leonard B. Bacharier, MD, FACAAI
Advisor: DBV Technologies
Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi
Researcher: AstraZeneca, Sanofi
Speaker: Regeneron, Sanofi

Alan P. Baptist, MD, MPH, FACAAI
Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi
Researcher: AstraZeneca, Novartis, Regeneron

This podcast miniseries is supported by a grant from AstraZeneca.
...more
23min
October 17, 2024The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 2
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 2: Implementing an Anti-inflammatory Reliever in Mild Asthma

Host: Gerald B. Lee, MD, FACAAI
Experts: William C. Anderson III, MD, FACAAI, Leonard B. Bacharier, MD, FACAAI

Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: anti-inflammatory reliever (AIR), pediatric vs. adult patients, GINA guidelines, insurance challenges.

Learning Objectives:
Expose the prevalence of asthma and exacerbations in the US
Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
Analyze the latest expert opinion on treatment of asthma to mitigate morbidity

Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.

Speaker Disclosures:
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose

William C. Anderson III, MD, FACAAI
Advisor: Genentech, Regeneron, Sanofi

Leonard B. Bacharier, MD, FACAAI
Advisor: DBV Technologies
Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi
Researcher: AstraZeneca, Sanofi
Speaker: Regeneron, Sanofi

This podcast miniseries is supported by a grant from AstraZeneca.
...more
19min
October 17, 2024The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 1
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 1: The Limitations of Bronchodilator Only Rescue Therapy

Host: Gerald B. Lee, MD, FACAAI
Experts: William C. Anderson III, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI

Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: pathophysiology, exacerbations, anti-inflammatory reliever (AIR), SMART therapy.

Learning Objectives:
Expose the prevalence of asthma and exacerbations in the US
Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
Analyze the latest expert opinion on treatment of asthma to mitigate morbidity

Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.

Speaker Disclosures:
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose

William C. Anderson III, MD, FACAAI
Advisor: Genentech, Regeneron, Sanofi

Alan P. Baptist, MD, MPH, FACAAI
Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi
Researcher: AstraZeneca, Novartis, Regeneron

This podcast miniseries is supported by a grant from AstraZeneca.
...more
14min
September 11, 2024 Episode 45 - Should We Wait To Skin Test After A Food Allergy Reaction? AllergyWatch Jan/Feb 2024
Welcome to Season Three of Allergytalk!
Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Gut microbiota maturity mediates the protective effect of siblings on food allergy.
Duration of skin prick test refractory period following food-induced allergic reactions.
Clinical and immunological phenotypes of selective IgM deficiency in children: Results from a multicenter study.
Please rate our podcast on Apple Podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis.
Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt
Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy
...more
25min
September 11, 2024 Episode 44 - How Does Tryptase Genetics Affect Food Allergy Reactions?
Welcome to Season Three of Allergytalk!
Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Outcomes of oral food challenges in a real-world setting, with predictors of outcomes.
Severe food allergy reactions are associated with α-tryptase.
Association of a Housing Mobility Program With Childhood Asthma Symptoms and Exacerbations.
Please rate our podcast on Apple Podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis.
Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt
Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy
...more
28min

FAQs about allergytalk:

How many episodes does allergytalk have?

The podcast currently has 74 episodes available.

More shows like allergytalk

Making Sense with Sam Harris by Sam Harris

Making Sense with Sam Harris

26,138 Listeners

JAMA Clinical Reviews by JAMA Network

JAMA Clinical Reviews

462 Listeners

The NPR Politics Podcast by NPR

The NPR Politics Podcast

25,408 Listeners

10% Happier with Dan Harris by Ten Percent Happier

10% Happier with Dan Harris

12,444 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,259 Listeners

The Daily by The New York Times

The Daily

109,999 Listeners

Up First from NPR by NPR

Up First from NPR

55,518 Listeners

Core IM | Internal Medicine Podcast by Core IM Team

Core IM | Internal Medicine Podcast

1,035 Listeners

AAAAI Podcast: Conversations from the World of Allergy by The American Academy of Allergy, Asthma & Immunology (AAAAI)

AAAAI Podcast: Conversations from the World of Allergy

47 Listeners

The Itch: Allergies, Asthma, Eczema & Immunology by The Itch: Allergies, Asthma & Immunology

The Itch: Allergies, Asthma, Eczema & Immunology

84 Listeners

The Happiness Lab with Dr. Laurie Santos by Pushkin Industries

The Happiness Lab with Dr. Laurie Santos

14,420 Listeners

The Cribsiders by The Cribsiders

The Cribsiders

300 Listeners

Breaking Points with Krystal and Saagar by iHeartPodcasts

Breaking Points with Krystal and Saagar

9,214 Listeners

JACI: In Practice Issue Highlights by Journal of Allergy and Clinical Immunology: In Practice (JACI)

JACI: In Practice Issue Highlights

2 Listeners